Form 4: Akari Therapeutics Director Donald A. Williams Granted Stock Options

Donald A. Williams, a director at Akari Therapeutics Plc, was granted 5,000,000 stock options under the company's 2023 Equity Incentive Plan.

Summary

• On June 28, 2024, Donald A. Williams, a director of Akari Therapeutics Plc, was granted 5,000,000 stock options.
• The options have an exercise price of $0.001395 per ordinary share.
• The stock options were granted under the Issuer's 2023 Equity Incentive Plan.
• The options vest and become exercisable on the date of the Issuer's 2025 Annual General Meeting of Shareholders, subject to continued service with the Issuer.
• Williams also has a Power of Attorney agreement in place, effective December 13, 2023, authorizing Rachelle Jacques and Wendy F. DiCicco to act on his behalf in matters related to securities filings.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of granting stock options to a director, which is generally viewed positively as it aligns interests with shareholders. The vesting schedule also suggests a commitment to long-term value creation.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service with the company.

Future Outlook

The stock options vest and become exercisable on the date of the Issuer's 2025 Annual General Meeting of Shareholders, subject to continued service with the Issuer.

Industry Context

Granting stock options to directors is a common practice to align their interests with those of shareholders and incentivize long-term value creation. This is a standard component of executive compensation packages in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule until the 2025 AGM is a fairly standard vesting period, incentivizing continued service.
• Comparable companies often use similar equity incentive plans to attract and retain key personnel.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with theirs.
• The vesting schedule incentivizes the director to contribute to the company's long-term success.

Next Steps

• The stock options will vest on the date of the 2025 Annual General Meeting of Shareholders, subject to continued service.
• Donald A. Williams may exercise the options after the vesting date.

Key Dates